JP2022501031A5 - - Google Patents

Info

Publication number
JP2022501031A5
JP2022501031A5 JP2021515177A JP2021515177A JP2022501031A5 JP 2022501031 A5 JP2022501031 A5 JP 2022501031A5 JP 2021515177 A JP2021515177 A JP 2021515177A JP 2021515177 A JP2021515177 A JP 2021515177A JP 2022501031 A5 JP2022501031 A5 JP 2022501031A5
Authority
JP
Japan
Prior art keywords
car
cells
culture
modified immune
immune cells
Prior art date
Application number
JP2021515177A
Other languages
English (en)
Japanese (ja)
Other versions
JP7716976B2 (ja
JPWO2020061256A5 (https=
JP2022501031A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051832 external-priority patent/WO2020061256A1/en
Publication of JP2022501031A publication Critical patent/JP2022501031A/ja
Publication of JPWO2020061256A5 publication Critical patent/JPWO2020061256A5/ja
Publication of JP2022501031A5 publication Critical patent/JP2022501031A5/ja
Priority to JP2025044165A priority Critical patent/JP2025106298A/ja
Application granted granted Critical
Publication of JP7716976B2 publication Critical patent/JP7716976B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515177A 2018-09-19 2019-09-19 キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ Active JP7716976B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025044165A JP2025106298A (ja) 2018-09-19 2025-03-19 キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733291P 2018-09-19 2018-09-19
US62/733,291 2018-09-19
PCT/US2019/051832 WO2020061256A1 (en) 2018-09-19 2019-09-19 Protein l for activation and expansion of chimeric antigen receptor-modified immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025044165A Division JP2025106298A (ja) 2018-09-19 2025-03-19 キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ

Publications (4)

Publication Number Publication Date
JP2022501031A JP2022501031A (ja) 2022-01-06
JPWO2020061256A5 JPWO2020061256A5 (https=) 2022-08-12
JP2022501031A5 true JP2022501031A5 (https=) 2022-08-12
JP7716976B2 JP7716976B2 (ja) 2025-08-01

Family

ID=68085017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515177A Active JP7716976B2 (ja) 2018-09-19 2019-09-19 キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ
JP2025044165A Withdrawn JP2025106298A (ja) 2018-09-19 2025-03-19 キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025044165A Withdrawn JP2025106298A (ja) 2018-09-19 2025-03-19 キメラ抗原受容体改変免疫細胞の活性化及び拡大培養のためのプロテインｌ

Country Status (10)

Country Link
US (1) US12533414B2 (https=)
EP (1) EP3853351A1 (https=)
JP (2) JP7716976B2 (https=)
KR (1) KR20210061397A (https=)
CN (1) CN112739816B (https=)
AU (1) AU2019345052B2 (https=)
CA (1) CA3110706A1 (https=)
IL (1) IL281413B2 (https=)
SG (1) SG11202102654UA (https=)
WO (1) WO2020061256A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021255189A1 (en) * 2020-06-17 2021-12-23 Tiziana Life Sciences, Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
MX2023011927A (es) 2021-04-07 2023-10-23 Century Therapeutics Inc Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
US20220333074A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
JP7738826B2 (ja) * 2021-10-29 2025-09-16 東ソー株式会社 遺伝子改変ｔ細胞の製造方法
CN113980901B (zh) * 2021-12-28 2022-06-17 上海惠盾因泰生物科技有限公司 一种制备高纯度的成熟人树突状细胞的方法及应用
JPWO2024242080A1 (https=) * 2023-05-22 2024-11-28

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144339A0 (en) 1999-01-28 2002-05-23 Palmetto Health Alliance A cell line containing gamma delta lymphocytes and pharmaceutical compositions containing the same
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
AU2006298188B2 (en) * 2005-09-30 2012-03-15 Takara Bio Inc. Method for production of T cell population
WO2008111430A1 (ja) 2007-03-09 2008-09-18 Takara Bio Inc. γδＴ細胞集団の製造方法
CN102046780A (zh) 2008-03-27 2011-05-04 宝生物工程株式会社 转染的细胞的生产方法
KR101720961B1 (ko) 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
CN102816734A (zh) * 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
EP3352571A1 (en) 2015-09-25 2018-08-01 Flechsig Patent Company LLC Novel plant protecting compositions and uses thereof
CN108431211B (zh) 2015-10-20 2026-03-24 富士胶片细胞动力公司 通过遗传编程的多谱系造血前体细胞产生
MX2018005274A (es) 2015-10-30 2019-09-19 The Regents Of The Universtiy Of California Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
CA3003152A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
MY185961A (en) 2015-11-04 2021-06-14 Univ Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
RU2021107053A (ru) * 2016-03-16 2021-08-24 Нексиммьюн, Инк. Получение антигенспецифических t-клеток
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2021200901A1 (ja) 2020-03-31 2021-10-07 国立大学法人京都大学 Ｔ前駆細胞の製造方法

Similar Documents

Publication Publication Date Title
JP2022501031A5 (https=)
MacDonald et al. Methods to manufacture regulatory T cells for cell therapy
Knorr et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy
US8071374B2 (en) Methods for preparing T-cells for cell therapy
Shimasaki et al. Expanded and armed natural killer cells for cancer treatment
Angoulvant et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens.
CN108473959B (zh) 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
US10172887B2 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2020517237A5 (https=)
CN107002039B (zh) 使用t细胞用于培养自然杀伤细胞的方法
Ye et al. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes
JP2018515108A (ja) 準静的細胞培養
CN102428173A (zh) Nk细胞的扩增
JPWO2020168300A5 (https=)
US20210371820A1 (en) Method for amplifying antigen-specific regulatory t cells in vitro
CN115491354B (zh) 一种nk细胞分化的方法
US20070258959A1 (en) CD4+CD25- T CELLS AND Tr1-LIKE REGULATORY T CELLS
JPWO2020061256A5 (https=)
Li et al. Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells
Good et al. Using human induced pluripotent stem cells for the generation of tumor antigen-specific T cells
CN102802686A (zh) 骨髓胞外基质提取物及其治疗用途
Williams et al. In vitro T lymphopoiesis: iPSCs for T cell generation, foundations, innovations, and future directions
Wilson et al. Stem Cell-Derived Cell Therapy for Cancer
HK40064965A (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
Liu et al. Proliferative and regenerative capacities of CD4+ T cells upon TCR stimulation